{"id":3143,"date":"2025-11-07T14:09:09","date_gmt":"2025-11-07T13:09:09","guid":{"rendered":"https:\/\/www.monitorcm.se\/?p=3143"},"modified":"2025-11-07T14:09:09","modified_gmt":"2025-11-07T13:09:09","slug":"kop-aktier-i-sigrid-therapeutics-ab","status":"publish","type":"post","link":"https:\/\/www.monitorcm.se\/en\/kop-aktier-i-sigrid-therapeutics-ab\/","title":{"rendered":"Buy shares in Sigrid Therapeutics AB"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Sigrid Therapeutics \u00e4r ett svenskt life science-bolag som utvecklar vetenskapligt validerade l\u00f6sningar f\u00f6r metabol h\u00e4lsa. Med huvudkontor i Stockholm och samarbeten med v\u00e4rldsledande forskningsinstitutioner kombinerar Sigrid banbrytande forskning med kommersiell innovation. M\u00e5let \u00e4r att erbjuda s\u00e4kra, icke-farmaceutiska produkter som hj\u00e4lper m\u00e4nniskor att kontrollera blodsocker, vikt och allm\u00e4n \u00e4mnesoms\u00e4ttning.<\/span><\/p>\n<h2><b>Vetenskap i centrum<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Bolaget grundades 2014 av Sana Alajmovic och professor Tore Bengtsson, baserat p\u00e5 \u00f6ver ett decennium av forskning kring metabolism och kroniska livsstilssjukdomar. Deras gemensamma vision var att ta fram ett nytt s\u00e4tt att f\u00f6rebygga och hantera tillst\u00e5nd som prediabetes, typ 2-diabetes och fetma, utan l\u00e4kemedel och biverkningar.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Resultatet blev SiPore\u00ae-teknologin, en patenterad plattform byggd p\u00e5 bio-ingenj\u00f6rda kiseldioxidpartiklar som verkar lokalt i tarmen. Genom att bromsa nedbrytningen av kolhydrater och fetter kan SiPore\u00ae s\u00e4nka blodsockertoppar, f\u00f6rb\u00e4ttra kolesterolv\u00e4rden och bidra till en stabilare energibalans. Tekniken \u00e4r s\u00e4ker, testad i flera kliniska studier och har god tolerabilitet eftersom den inte absorberas i kroppen.<\/span><\/p>\n<h2><b>Fr\u00e5n forskning till marknad<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Sigrid Therapeutics har g\u00e5tt fr\u00e5n laboratorieforskning till kommersiell fas med tv\u00e5 marknadsklara produkter.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Carb Fence\u2122<\/b><span style=\"font-weight: 400;\">, en medicinsk n\u00e4ringsprodukt framtagen f\u00f6r personer med prediabetes, diabetes eller viktproblematik.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Glucose Stabiliser<\/b><span style=\"font-weight: 400;\">, ett kosttillskott som fr\u00e4mjar daglig blodsockerbalans och \u00e4mnesoms\u00e4ttning.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Produkterna baseras p\u00e5 SiPore\u00ae-plattformen och finns tillg\u00e4ngliga b\u00e5de i Sverige och internationellt. Parallellt utv\u00e4rderas teknologin inom omr\u00e5den som oral h\u00e4lsa, funktionella livsmedel och veterin\u00e4rv\u00e5rd, vilket visar dess breda anv\u00e4ndningspotential.<\/span><\/p>\n<h2><b>Ledning och vetenskaplig kompetens<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Bakom bolaget st\u00e5r ett tv\u00e4rvetenskapligt team med l\u00e5ng erfarenhet inom fysiologi, kemi, farmakologi och aff\u00e4rsutveckling. F\u00f6rutom grundarna ing\u00e5r bland andra Eric Johnston (CTO &amp; COO) och Kasper Wickz\u00e9n (CCO) i ledningen. Bolaget st\u00f6ds \u00e4ven av en vetenskaplig r\u00e5dgivningsgrupp best\u00e5ende av internationellt erk\u00e4nda forskare inom metabola sjukdomar.<\/span><\/p>\n<h2><b>M\u00f6jlighet att investera i Sigrid Therapeutics<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Sigrid Therapeutics AB \u00e4r ett onoterat bolag, vilket inneb\u00e4r att aktien inte handlas p\u00e5 n\u00e5gon b\u00f6rs. Genom Monitor Capital Markets, en licensierad m\u00e4klare under Finansinspektionens tillsyn, kan investerare i vissa fall ges m\u00f6jlighet att handla aktier i bolaget. Handeln sker genom matchning mellan k\u00f6pare och s\u00e4ljare och ska inte betraktas som ett offentligt erbjudande.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Att investera i onoterade bolag inneb\u00e4r h\u00f6gre risk och begr\u00e4nsad likviditet. Det finns ingen garanti f\u00f6r framtida avkastning. Informationen p\u00e5 denna sida \u00e4r generell och utg\u00f6r inte investeringsr\u00e5dgivning. Den som \u00f6verv\u00e4ger att investera b\u00f6r ta del av bolagets publika information och vid behov r\u00e5dg\u00f6ra med en oberoende r\u00e5dgivare.<\/span><\/p>\n<p><b>Are you interested in investing?<\/b><\/p>\n<p><a href=\"https:\/\/www.monitorcm.se\/en\/contact\/\"><span style=\"font-weight: 400;\">Contact us<\/span><\/a><span style=\"font-weight: 400;\"> for more information on how to trade and how you can become a shareholder.<\/span><\/p>\n<h3><b>Other unlisted companies investors follow<\/b><\/h3>\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.monitorcm.se\/en\/kopa-aktier-i-bankaktiebolaget-nordiska\/\">Nordic countries<\/a> | <a href=\"https:\/\/www.monitorcm.se\/en\/att-kopa-aktier-i-nicoya-ab\/\">Nicoya AB<\/a> | <a href=\"https:\/\/www.monitorcm.se\/en\/kop-aktier-i-kaunis-iron-hos-monitor-capital-markets\/\">Kaunis Iron<\/a> | <a href=\"https:\/\/www.monitorcm.se\/en\/handla-aktier-i-greengold-group\/\">Exeger<\/a><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Sigrid Therapeutics \u00e4r ett svenskt life science-bolag som utvecklar vetenskapligt validerade l\u00f6sningar f\u00f6r metabol h\u00e4lsa. Med huvudkontor i Stockholm och samarbeten med v\u00e4rldsledande forskningsinstitutioner kombinerar Sigrid banbrytande forskning med kommersiell innovation. M\u00e5let \u00e4r att erbjuda s\u00e4kra, icke-farmaceutiska produkter som hj\u00e4lper m\u00e4nniskor att kontrollera blodsocker, vikt och allm\u00e4n \u00e4mnesoms\u00e4ttning. Vetenskap i centrum Bolaget grundades 2014 av [&#8230;]\n","protected":false},"author":2,"featured_media":3144,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[60],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>K\u00f6p aktier i Sigrid Therapeutics AB &#8211; Monitor Capital Markets<\/title>\n<meta name=\"description\" content=\"Sigrid Therapeutics utvecklar vetenskapligt baserade produkter f\u00f6r b\u00e4ttre blodsocker, viktkontroll och metabol h\u00e4lsa genom sin patenterade teknologi.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.monitorcm.se\/en\/kop-aktier-i-sigrid-therapeutics-ab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"K\u00f6p aktier i Sigrid Therapeutics AB &#8211; Monitor Capital Markets\" \/>\n<meta property=\"og:description\" content=\"Sigrid Therapeutics utvecklar vetenskapligt baserade produkter f\u00f6r b\u00e4ttre blodsocker, viktkontroll och metabol h\u00e4lsa genom sin patenterade teknologi.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.monitorcm.se\/en\/kop-aktier-i-sigrid-therapeutics-ab\/\" \/>\n<meta property=\"og:site_name\" content=\"Monitor Capital Markets\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T13:09:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"999\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pontus N\u00e4ss\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pontus N\u00e4ss\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/\"},\"author\":{\"name\":\"Pontus N\u00e4ss\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355\"},\"headline\":\"K\u00f6p aktier i Sigrid Therapeutics AB\",\"datePublished\":\"2025-11-07T13:09:09+00:00\",\"dateModified\":\"2025-11-07T13:09:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/\"},\"wordCount\":490,\"publisher\":{\"@id\":\"https:\/\/www.monitorcm.se\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg\",\"articleSection\":[\"Nyheter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/\",\"url\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/\",\"name\":\"K\u00f6p aktier i Sigrid Therapeutics AB &#8211; Monitor Capital Markets\",\"isPartOf\":{\"@id\":\"https:\/\/www.monitorcm.se\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg\",\"datePublished\":\"2025-11-07T13:09:09+00:00\",\"dateModified\":\"2025-11-07T13:09:09+00:00\",\"description\":\"Sigrid Therapeutics utvecklar vetenskapligt baserade produkter f\u00f6r b\u00e4ttre blodsocker, viktkontroll och metabol h\u00e4lsa genom sin patenterade teknologi.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage\",\"url\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg\",\"contentUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg\",\"width\":999,\"height\":767,\"caption\":\"K\u00f6p aktier i sigrid therapeutics ab\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\/\/www.monitorcm.se\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00f6p aktier i Sigrid Therapeutics AB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.monitorcm.se\/#website\",\"url\":\"https:\/\/www.monitorcm.se\/\",\"name\":\"Monitor Capital Markets\",\"description\":\"Finansiellt M\u00e4kleri med fokus p\u00e5 onoterade bolag och aktier\",\"publisher\":{\"@id\":\"https:\/\/www.monitorcm.se\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.monitorcm.se\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.monitorcm.se\/#organization\",\"name\":\"Monitor Capital Markets\",\"url\":\"https:\/\/www.monitorcm.se\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png\",\"contentUrl\":\"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png\",\"width\":720,\"height\":120,\"caption\":\"Monitor Capital Markets\"},\"image\":{\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/monitor-capital-markets\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355\",\"name\":\"Pontus N\u00e4ss\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"K\u00f6p aktier i Sigrid Therapeutics AB &#8211; Monitor Capital Markets","description":"Sigrid Therapeutics utvecklar vetenskapligt baserade produkter f\u00f6r b\u00e4ttre blodsocker, viktkontroll och metabol h\u00e4lsa genom sin patenterade teknologi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.monitorcm.se\/en\/kop-aktier-i-sigrid-therapeutics-ab\/","og_locale":"en_US","og_type":"article","og_title":"K\u00f6p aktier i Sigrid Therapeutics AB &#8211; Monitor Capital Markets","og_description":"Sigrid Therapeutics utvecklar vetenskapligt baserade produkter f\u00f6r b\u00e4ttre blodsocker, viktkontroll och metabol h\u00e4lsa genom sin patenterade teknologi.","og_url":"https:\/\/www.monitorcm.se\/en\/kop-aktier-i-sigrid-therapeutics-ab\/","og_site_name":"Monitor Capital Markets","article_published_time":"2025-11-07T13:09:09+00:00","og_image":[{"width":999,"height":767,"url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg","type":"image\/jpeg"}],"author":"Pontus N\u00e4ss","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pontus N\u00e4ss","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#article","isPartOf":{"@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/"},"author":{"name":"Pontus N\u00e4ss","@id":"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355"},"headline":"K\u00f6p aktier i Sigrid Therapeutics AB","datePublished":"2025-11-07T13:09:09+00:00","dateModified":"2025-11-07T13:09:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/"},"wordCount":490,"publisher":{"@id":"https:\/\/www.monitorcm.se\/#organization"},"image":{"@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg","articleSection":["Nyheter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/","url":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/","name":"K\u00f6p aktier i Sigrid Therapeutics AB &#8211; Monitor Capital Markets","isPartOf":{"@id":"https:\/\/www.monitorcm.se\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage"},"image":{"@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg","datePublished":"2025-11-07T13:09:09+00:00","dateModified":"2025-11-07T13:09:09+00:00","description":"Sigrid Therapeutics utvecklar vetenskapligt baserade produkter f\u00f6r b\u00e4ttre blodsocker, viktkontroll och metabol h\u00e4lsa genom sin patenterade teknologi.","breadcrumb":{"@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#primaryimage","url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg","contentUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2025\/11\/Sigrid-therapeutics-ab.jpg","width":999,"height":767,"caption":"K\u00f6p aktier i sigrid therapeutics ab"},{"@type":"BreadcrumbList","@id":"https:\/\/www.monitorcm.se\/kop-aktier-i-sigrid-therapeutics-ab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.monitorcm.se\/"},{"@type":"ListItem","position":2,"name":"K\u00f6p aktier i Sigrid Therapeutics AB"}]},{"@type":"WebSite","@id":"https:\/\/www.monitorcm.se\/#website","url":"https:\/\/www.monitorcm.se\/","name":"Monitor Capital Markets","description":"Financial Brokerage with focus on unlisted companies and shares","publisher":{"@id":"https:\/\/www.monitorcm.se\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.monitorcm.se\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.monitorcm.se\/#organization","name":"Monitor Capital Markets","url":"https:\/\/www.monitorcm.se\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/","url":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png","contentUrl":"https:\/\/www.monitorcm.se\/wp-content\/uploads\/2018\/08\/monitor_capital_markets_logo.png","width":720,"height":120,"caption":"Monitor Capital Markets"},"image":{"@id":"https:\/\/www.monitorcm.se\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/monitor-capital-markets\/"]},{"@type":"Person","@id":"https:\/\/www.monitorcm.se\/#\/schema\/person\/408afedad07610f4f094467bc4010355","name":"Pontus N\u00e4ss"}]}},"_links":{"self":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3143"}],"collection":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/comments?post=3143"}],"version-history":[{"count":1,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3143\/revisions"}],"predecessor-version":[{"id":3145,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/posts\/3143\/revisions\/3145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/media\/3144"}],"wp:attachment":[{"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/media?parent=3143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/categories?post=3143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.monitorcm.se\/en\/wp-json\/wp\/v2\/tags?post=3143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}